Recombinant Human IL-28A/IFN-lambda 2 Protein

• Reactivity: Hu
• Applications: Bioactivity

Recombinant Human IL-28A/IFN-lambda 2 Protein Summary

• Details of Functionality: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 0.800-8.00 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human IL-28A/IFN-lambda 2 protein
  

  Human IL-28A Val26-Val200 Accession # NP_742150	DI	6-His tag
  N-terminus		C-terminus

• Accession #: NP_742150
• N-terminal Sequence: Val26
• Protein/Peptide Type: Recombinant Proteins
• Gene: IFNL2
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 20.8 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 24 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-28A/IFN-lambda 2 Protein

• interleukin-28A
• IFN-lambda 2
• IL28A
• IL-28A
• interferon, lambda 2

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon. The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor alpha (IL-28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Publications for IL-28A/IFN-lambda 2 (1587-IL)(13)

Publications using 1587-IL

• M Syedbasha, F Bonfiglio, J Linnik, C Stuehler, D Wüthrich, A Egli Interferon-&amp;lambda Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway Cell Rep, 2020-10-06;33(1):108211. 2020-10-06 [PMID: 33027651] (Bioassay, Human)
• A Pierangeli, M Statzu, R Nenna, L Santinelli, L Petrarca, A Frassanito, M Gentile, G Antonelli, F Midulla, C Scagnolari Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity J. Clin. Virol., 2018-03-10;102(0):101-109. 2018-03-10 [PMID: 29549834] (Stimulation, Human)
• J Corry, N Arora, CA Good, Y Sadovsky, CB Coyne Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface Proc. Natl. Acad. Sci. U.S.A., 2017-08-07;0(0):. 2017-08-07 [PMID: 28784796] (Bioassay, Human)
• PS Sung, SH Hong, JH Chung, S Kim, SH Park, HM Kim, SK Yoon, EC Shin IFN-?4 potently blocks IFN-? signalling by ISG15 and USP18 in hepatitis C virus infection Sci Rep, 2017-06-19;7(1):3821. 2017-06-19 [PMID: 28630501] (Bioassay, Human)
• Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling Nat. Med., 2016-11-14;0(0):. 2016-11-14 [PMID: 27841874] (Bioassay, Human)
• Persson B, Jaffe A, Fearns R, Danahay H Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS ONE, 2014-07-17;9(7):e102368. 2014-07-17 [PMID: 25033192] (Bioassay, Human)
• Ding S, Khoury-Hanold W, Iwasaki A, Robek M Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol, 2014-01-07;12(1):e1001758. 2014-01-07 [PMID: 24409098] (Bioassay, Human)
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)
• Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-kappaB-mediated MMP-9 expression inducing the MAPK pathway. Cell. Signal., 2012-04-25;24(9):1734-42. 2012-04-25 [PMID: 22560878] (Bioassay, Human)
• Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects. Br. J. Cancer, 2011-09-27;105(9):1302-12. 2011-09-27 [PMID: 21952623] (Bioassay, Human)
• Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun., 2009-10-01;10(8):702-14. 2009-10-01 [PMID: 19798076] (Bioassay, Human)
• Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer, 2009-07-15;125(2):367-73. 2009-07-15 [PMID: 19378341] (Bioassay, Human)
• Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine, 2005-07-21;31(2):109-18. 2005-07-21 [PMID: 15899585] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IFNL2
• Uniprot:
  • NP_742150()